恒瑞医药 reported revenue of ¥15.46B for the period ended 2026-06-30, -1.9% year on year. Net income was ¥4.47B, a 28.9% net margin on a 86.3% gross margin. The largest revenue line is 销售商品 at 90% of the total. Free cash flow for the period was ¥0.33B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥15.46B | -1.9% |
| Gross profit | ¥13.34B | — |
| Operating income | ¥5.09B | — |
| Net income | ¥4.47B | +0.2% |
| Gross margin | 86.3% | Net margin 28.9% |
| Revenue Q/Q | -10.1% | — |
| Segment | Revenue | Share |
|---|---|---|
| 销售商品 | ¥13.95B | 90.2% |
| 许可收入 | ¥1.42B | 9.2% |
| 其他 | ¥0.09B | 0.6% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥2.11B | 13.7% |
| R&D | ¥3.49B | 22.6% |
| SG&A | ¥5.60B | 36.2% |
| Tax & other | ¥0.62B | 4.0% |
| Item | Amount |
|---|---|
| Total assets | ¥70.77B |
| Total liabilities | ¥5.78B |
| Shareholders' equity | ¥64.99B |
| Equity / assets | 91.8% |
| Operating cash flow | ¥1.20B |
| Capital expenditure | ¥0.87B |
| Free cash flow | ¥0.33B |
| Cash conversion (OCF / net income) | 44% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
万华化学 ・ 恒力石化 ・ 江西铜业 ・ 中航机载 ・ 国电南瑞 ・ 小商品城 ・ 华鲁恒升 ・ 片仔癀 ・ 通威股份 ・ 士兰微 ・ 中国动力 ・ 中金黄金
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies